Literature DB >> 22634524

Comparative distribution of protein components of the A20 ubiquitin-editing complex in normal human brain.

Elaine L Pranski1, Carson D Van Sanford, Nirjari V Dalal, Adam L Orr, Dipan Karmali, Deborah S Cooper, Nichole Costa, Craig J Heilman, Marla Gearing, James J Lah, Allan I Levey, Ranjita S Betarbet.   

Abstract

Activation of innate and adaptive immune responses is tightly regulated, as insufficient activation could result in defective clearance of pathogens, while excessive activation might lead to lethal systemic inflammation or autoimmunity. A20 functions as a negative regulator of innate and adaptive immunity by inhibiting NF-κB activation. A20 mediates its inhibitory function in a complex with other proteins including RNF11 and Itch, both E3 ubiquitin ligases and TAX1BP1, an adaptor protein. Since NF-κB has been strongly implicated in various neuronal functions, we predict that its inhibitor, the A20 complex, is also present in the nervous system. In efforts to better understand the role of A20 complex and NF-κB signaling pathway, we determined regional distribution of A20 mRNA as well as protein expression levels and distribution of RNF11, TAX1BP1 and Itch, in different brain regions. The distribution of TRAF6 was also investigated since TRAF6, also an E3 ligase, has an important role in NF-κB signaling pathway. Our investigations, for the first time, describe and demonstrate that the essential components of the A20 ubiquitin-editing complex are present and mainly expressed in neurons. The A20 complex components are also differentially expressed throughout the human brain. This study provides useful information about region specific expression of the A20 complex components that will be invaluable while determining the role of NF-κB signaling pathway in neuronal development and degeneration.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634524      PMCID: PMC3375179          DOI: 10.1016/j.neulet.2012.05.043

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  30 in total

Review 1.  Pattern recognition receptors and inflammation.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease.

Authors:  Naomi J Lohr; Jean P Molleston; Kevin A Strauss; Wilfredo Torres-Martinez; Eric A Sherman; Robert H Squires; Nicholas L Rider; Kudakwashe R Chikwava; Oscar W Cummings; D Holmes Morton; Erik G Puffenberger
Journal:  Am J Hum Genet       Date:  2010-02-18       Impact factor: 11.025

3.  Tax1-binding protein 1 is expressed in the retina and interacts with the GABA(C) receptor rho1 subunit.

Authors:  Melanie Ulrich; Silke Seeber; Cord-Michael Becker; Ralf Enz
Journal:  Biochem J       Date:  2007-01-15       Impact factor: 3.857

Review 4.  Novel RING E3 ubiquitin ligases in breast cancer.

Authors:  Angelika Burger; Yutaka Amemiya; Richard Kitching; Arun K Seth
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

Review 5.  Mechanisms underlying inflammation in neurodegeneration.

Authors:  Christopher K Glass; Kaoru Saijo; Beate Winner; Maria Carolina Marchetto; Fred H Gage
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

6.  Striatal 19S Rpt6 deficit is related to alpha-synuclein accumulation in MPTP-treated mice.

Authors:  Bin Liu; Qiaoqiao Shi; Shiping Ma; Nan Feng; Jiang Li; Ling Wang; Xiaoliang Wang
Journal:  Biochem Biophys Res Commun       Date:  2008-09-07       Impact factor: 3.575

7.  Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats.

Authors:  Melissa K McCoy; Kelly A Ruhn; Terina N Martinez; Fiona E McAlpine; Armin Blesch; Malú G Tansey
Journal:  Mol Ther       Date:  2008-07-15       Impact factor: 11.454

8.  Fas-associated factor 1 and Parkinson's disease.

Authors:  Ranjita Betarbet; Leah R Anderson; Marla Gearing; Tiffany R Hodges; Jason J Fritz; James J Lah; Allan I Levey
Journal:  Neurobiol Dis       Date:  2008-05-29       Impact factor: 5.996

9.  The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling.

Authors:  Noula Shembade; Kislay Parvatiyar; Nicole S Harhaj; Edward W Harhaj
Journal:  EMBO J       Date:  2009-01-08       Impact factor: 11.598

10.  BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources.

Authors:  Chunlei Wu; Camilo Orozco; Jason Boyer; Marc Leglise; James Goodale; Serge Batalov; Christopher L Hodge; James Haase; Jeff Janes; Jon W Huss; Andrew I Su
Journal:  Genome Biol       Date:  2009-11-17       Impact factor: 13.583

View more
  12 in total

1.  RNF11 modulates microglia activation through NF-κB signalling cascade.

Authors:  Nirjari V Dalal; Elaine L Pranski; Malu G Tansey; James J Lah; Allan I Levey; Ranjita S Betarbet
Journal:  Neurosci Lett       Date:  2012-09-11       Impact factor: 3.046

2.  RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells.

Authors:  Elaine L Pranski; Nirjari V Dalal; Carson Van Sanford; Jeremy H Herskowitz; Marla Gearing; Carlos Lazo; Gary W Miller; James J Lah; Allan I Levey; Ranjita S Betarbet
Journal:  Neurobiol Dis       Date:  2013-01-11       Impact factor: 5.996

3.  TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-α and IL-1β signaling.

Authors:  Ying Lu; Bao-Chun Jiang; De-Li Cao; Zhi-Jun Zhang; Xin Zhang; Ru-Rong Ji; Yong-Jing Gao
Journal:  Pain       Date:  2014-10-19       Impact factor: 6.961

4.  A20 Ameliorates Intracerebral Hemorrhage-Induced Inflammatory Injury by Regulating TRAF6 Polyubiquitination.

Authors:  Zhaoyou Meng; Ting Zhao; Kai Zhou; Qi Zhong; Yanchun Wang; Xiaoyi Xiong; Faxiang Wang; Yuanrui Yang; Wenyao Zhu; Juan Liu; Maofan Liao; Lirong Wu; Chunmei Duan; Jie Li; Qiuwen Gong; Liang Liu; Ao Xiong; Meihua Yang; Jian Wang; Qingwu Yang
Journal:  J Immunol       Date:  2016-12-16       Impact factor: 5.422

5.  AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications.

Authors:  Xinping Huang; Antja-Voy Hartley; Yishi Yin; Jeremy H Herskowitz; James J Lah; Kerry J Ressler
Journal:  J Virol Methods       Date:  2013-06-19       Impact factor: 2.014

6.  NF-κB activity is inversely correlated to RNF11 expression in Parkinson's disease.

Authors:  Elaine Pranski; Carson D Van Sanford; Nirjari Dalal; Adam L Orr; Dipan Karmali; Deborah S Cooper; Marla Gearing; James J Lah; Allan I Levey; Ranjita Betarbet
Journal:  Neurosci Lett       Date:  2013-05-10       Impact factor: 3.046

7.  The ubiquitin-editing enzyme A20 regulates synapse remodeling and efficacy.

Authors:  Shaolin Mei; Hongyu Ruan; Qi Ma; Wei-Dong Yao
Journal:  Brain Res       Date:  2019-11-26       Impact factor: 3.610

8.  A20 deficiency causes spontaneous neuroinflammation in mice.

Authors:  Renata Padilha Guedes; Eva Csizmadia; Herwig P Moll; Averil Ma; Christiane Ferran; Cleide Gonçalves da Silva
Journal:  J Neuroinflammation       Date:  2014-07-16       Impact factor: 8.322

9.  Ring Finger Protein 11 (RNF11) Modulates Dopamine Release in Drosophila.

Authors:  Eve Privman Champaloux; Nathan Donelson; Poojan Pyakurel; Danielle Wolin; Leah Ostendorf; Madelaine Denno; Ryan Borman; Chris Burke; Jonah C Short-Miller; Maria R Yoder; Jeffrey M Copeland; Subhabrata Sanyal; B Jill Venton
Journal:  Neuroscience       Date:  2020-11-08       Impact factor: 3.590

10.  Upregulation of neuronal zinc finger protein A20 expression is required for electroacupuncture to attenuate the cerebral inflammatory injury mediated by the nuclear factor-kB signaling pathway in cerebral ischemia/reperfusion rats.

Authors:  Jian Zhan; Wenyi Qin; Ying Zhang; Jing Jiang; Hongmei Ma; Qiongli Li; Yong Luo
Journal:  J Neuroinflammation       Date:  2016-10-03       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.